Clinical Trials · NCT01836523
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 1,398
- Start date
- Nov 2013
- Locations
- 182 sites, 17 countries
- Primary endpoint
- Change From Baseline in HbA1c (Glycosylated Haemoglobin)